Aims To describe the population pharmacokinetic–pharmacodynamic relationship between
darifenacin (UK‐88,525) and its hydroxylated metabolite (UK‐148,993), and the reduction in …

Aims A model describing the population pharmacokinetics of darifenacin and its
hydroxylated metabolite was developed from a combined analysis of 18 studies. The …

Aims To characterize the pharmacokinetics of deferiprone in healthy subjects using a model‐
based approach and to assess the effect of demographic and physiological factors on drug …

A high performance thin layer chromatographic assay for dapsone is described with a
minimum level of detection of 20 ng ml− 1 which is suitable for the study of dapsone …

Aims The combination of daptomycin and ceftaroline used as salvage therapy is associated
with higher survival and decreased clinical failure in complicated methicillin‐resistant …

The pharmacokinetic profile of solifenacin succinate (YM905; Vesicare), a new once‐daily
bladder‐selective muscarinic receptor antagonist, was examined in 2 controlled trials of …

Deferasirox is a novel iron chelator formulated as tablets for dispersion (suspension) for
once‐a‐day oral administration. The current study evaluated the absolute bioavailability of a …

Darifenacin hydrobromide is a selective muscarinic M 3 receptor antagonist that is indicated
for use in treatment of overactive bladder disorder. Darifenacin was found to have a short …

Abstract Background and Objective Deferasirox is an oral iron chelator used to reduce iron
levels in iron-overloaded patients with transfusion-dependent anemia or non-transfusion …

The pharmacokinetics of dyphyiline, including the relationship of dyphylline plasma levels to
saliva levels and the metabolic fate of the drug, were studied. Six healthy fasting white men …